JPH10503364A - Ｃ型肝炎ウイルスのアンチセンス阻害 - Google Patents

Ｃ型肝炎ウイルスのアンチセンス阻害

Info

Publication number
JPH10503364A
JPH10503364A JP7529188A JP52918895A JPH10503364A JP H10503364 A JPH10503364 A JP H10503364A JP 7529188 A JP7529188 A JP 7529188A JP 52918895 A JP52918895 A JP 52918895A JP H10503364 A JPH10503364 A JP H10503364A
Authority
JP
Japan
Prior art keywords
oligonucleotide
nucleotide sequence
comprises seq
seq
oligo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP7529188A
Other languages
English (en)
Japanese (ja)
Inventor
隆字 脇田
ジャック アール． ワンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of JPH10503364A publication Critical patent/JPH10503364A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP7529188A 1994-05-10 1995-05-08 Ｃ型肝炎ウイルスのアンチセンス阻害 Ceased JPH10503364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24038294A 1994-05-10 1994-05-10
US08/240,382 1994-05-10
PCT/US1995/005812 WO1995030746A1 (fr) 1994-05-10 1995-05-08 Inhibition par oligonucleotides antisens du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
JPH10503364A true JPH10503364A (ja) 1998-03-31

Family

ID=22906305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7529188A Ceased JPH10503364A (ja) 1994-05-10 1995-05-08 Ｃ型肝炎ウイルスのアンチセンス阻害

Country Status (4)

Country Link
US (1) US6001990A (fr)
EP (1) EP0759979A4 (fr)
JP (1) JPH10503364A (fr)
WO (1) WO1995030746A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004078974A1 (ja) * 2003-01-24 2006-06-08 財団法人 東京都医学研究機構 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
WO2007052629A1 (fr) * 2005-11-01 2007-05-10 Nippon Shinyaku Co., Ltd. Oligo-arn a double brin et composition pharmaceutique

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
IT1297096B1 (it) * 1997-12-03 1999-08-03 Sorin Diagnostics S R L Metodo per la rivelazione di analiti di dna a singola elica
EP1002878A3 (fr) * 1998-11-19 2003-11-12 Tosoh Corporation Oligo ADN se fixant sur ARN du virus de l'hépatite C et méthode de production
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2002125688A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｃ型肝炎ウイルスの高感度検出のためのオリゴヌクレオチドおよび検出法
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
CA2429814C (fr) * 2000-12-01 2014-02-18 Thomas Tuschl Petites molecules d'arn mediant l'interference arn
WO2002090572A2 (fr) * 2001-05-09 2002-11-14 Third Wave Technologies, Inc. Detection d'acides nucleiques dans des echantillons groupes
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
DK2280070T3 (en) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
EP1435974A4 (fr) * 2001-09-28 2006-09-06 Idenix Cayman Ltd Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
EP1352960A1 (fr) * 2002-04-12 2003-10-15 Viruvation B.V. Thérapie antivirale basée sur l'interférence ARN
AU2003261231A1 (en) 2002-07-26 2004-02-16 Chiron Corporation Modified small interfering rna molecules and methods of use
EP2163651A1 (fr) * 2002-07-26 2010-03-17 Abbott Laboratories Techniques de detection et de quantification du virus de l'hepatite C
US20040024193A1 (en) * 2002-07-26 2004-02-05 Williams Gregg T. Method of detecting and quantifying hepatitis C virus
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
FR2848572B1 (fr) * 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
EP2270162B1 (fr) * 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Séquences hbv et hcv conservées utiles pour silençage génique
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
ES2361458T5 (es) 2004-05-04 2016-04-20 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
AU2011250867A1 (en) * 2004-05-04 2011-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for reducing viral genome amounts in a target cell
WO2006031901A2 (fr) 2004-09-10 2006-03-23 Somagenics, Inc. Petits arn interferents inhibant efficacement l'expression genique virale et methodes d'utilisation associees
DE602005027479D1 (de) 2004-09-24 2011-05-26 Alnylam Pharmaceuticals Inc Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
WO2007084567A2 (fr) * 2006-01-17 2007-07-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection et discrimination de virus d’hepatite c, virus de l’immunodeficience humaine de type-1 et virus d’hepatite b
EP2007888A2 (fr) 2006-04-03 2008-12-31 Santaris Pharma A/S Composition pharmaceutique comprenant des oligonucleotides antisens anti-miarn
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2623599B1 (fr) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Oligonucléotides micromir
CA2717792A1 (fr) 2008-03-07 2009-09-11 Santaris Pharma A/S Compositions pharmaceutiques pour le traitement de maladies associees aux microarn
WO2010012667A1 (fr) 2008-08-01 2010-02-04 Santaris Pharma A/S Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
JP2012505657A (ja) 2008-10-15 2012-03-08 ソマジェニックス インク． 遺伝子発現の阻害のためのショートヘアピンｒｎａ
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2454371B1 (fr) 2009-07-13 2021-01-20 Somagenics, Inc. Modification chimique de petits arn en épingle à cheveux pour l'inhibition d'une expression de gène
EP2456870A1 (fr) 2009-07-21 2012-05-30 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US12005120B2 (en) 2018-05-08 2024-06-11 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
EP0384566A3 (fr) * 1989-01-27 1991-11-13 The Wistar Institute Amplification des séquences d'HTLV-I chez les patients atteints de sclérose multiple
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
JPH06500928A (ja) * 1990-08-29 1994-01-27 ザ・ウイスター・インスティテュート・オブ・アナトミー・アンド・バイオロジー 慢性疲労免疫不全症候群を診断および処置する方法ならびにそのための組成物
EP0516859A1 (fr) * 1990-11-29 1992-12-09 Toray Industries, Inc. Proteine anti-genique du virus de l'hepatite non a et non b
EP0571554A1 (fr) * 1991-01-14 1993-12-01 James N. Gamble Institute Of Medical Research Polypeptides immunogeniques structuraux de base ayant des epitopes pour vhc, anticorps, sequences de polynucleotides, vaccins et methodes
PL169880B1 (pl) * 1991-05-08 1996-09-30 Chiron Corp Sposób wytwarzania produktu hybrydyzacji z kwasem nukleinowym wirusa zapalenia watroby C PL PL PL
AT405053B (de) * 1991-06-10 1999-05-25 Lucky Ltd Hepatitis-c-diagnosemittel und -impfstoffe
KR950014915B1 (ko) * 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
EP0610436B9 (fr) * 1991-11-21 2003-03-26 Common Services Agency Recherche du virus de l'hepatite c
CA2136764A1 (fr) * 1992-05-29 1993-12-09 Ronald L. Marshall Reaction en chaine a la ligase a partir de sequences d'arn
CA2104649A1 (fr) * 1992-08-25 1994-02-26 Makoto Seki Molecules antisens complementaires de sequences genomiques de vhc
WO1994005813A1 (fr) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions et procedes pour le traitement d'affections associees au virus de l'hepatite c
EP0662128B1 (fr) * 1992-09-28 2005-11-23 Chiron Corporation Procedes et compositions de regulation de la translation de proteines hcv
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004078974A1 (ja) * 2003-01-24 2006-06-08 財団法人 東京都医学研究機構 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
WO2007052629A1 (fr) * 2005-11-01 2007-05-10 Nippon Shinyaku Co., Ltd. Oligo-arn a double brin et composition pharmaceutique

Also Published As

Publication number Publication date
EP0759979A4 (fr) 1999-10-20
WO1995030746A1 (fr) 1995-11-16
US6001990A (en) 1999-12-14
EP0759979A1 (fr) 1997-03-05

Similar Documents

Publication Publication Date Title
JPH10503364A (ja) Ｃ型肝炎ウイルスのアンチセンス阻害
EP1532248B1 (fr) Petites molecules modifiees d'arn d'interference et leurs procedes d'utilisation
AU2004263832B2 (en) Conserved HBV and HCV sequences useful for gene silencing
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
JP5934310B2 (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
US8138161B2 (en) Modified small interfering RNA molecules and methods of use
US9084808B2 (en) Modified small interfering RNA molecules and methods of use
JPH09507062A (ja) 抗ｂ型肝炎ウイルスオリゴヌクレオチド
AU2018200873B2 (en) Conserved HBV and HCV sequences useful for gene silencing
AU2013257445B2 (en) Conserved HBV and HCV sequences useful for gene silencing
US20090239933A1 (en) Hepatitis c antivirals

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050328

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050802